Treatment of paediatric scalp psoriasis with calcipotriene/betamethasone dipropionate scalp formulation: effectiveness, safety and influence on children's quality of life in daily practice

Oostveen, A.M.; Jong, E.M.G.J. de; Donders, A. Rogier T.; Kerkhof, P.C.M. van de; Seyger, M.M.B.

doi:10.1111/jdv.12789

Cited by 26 publications

(16 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to avoid separate applications and to enhance patient compliance, a commercially available compounded formulation containing calcipotriol and betamethasone dipropionate has been developed. Three studies describe the efficacy and safety of this formulation in pediatric psoriasis [ 69 – 71 ]. In a prospective study with a clinical practice cohort, 73 children (aged 3–18 years) with plaque type psoriasis were treated with calcipotriol/betamethasone dipropionate ointment once daily for 4 weeks and 4 days a week thereafter, with a median treatment duration of 35 weeks.…”

Section: Topical Treatmentsmentioning

confidence: 99%

“…Oostveen et al demonstrated the effectiveness of calcipotriene/betamethasone dipropionate gel in pediatric scalp psoriasis (patient ages 4–17 years) within the first 12 weeks of treatment (84 treatment episodes), with maintenance of this effect through the 48 weeks of follow-up. Striae of the skin (arms, trunk and legs) were described in three patients [ 71 ].…”

Section: Topical Treatmentsmentioning

confidence: 99%

See 1 more Smart Citation

Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities

et al. 2015

View full text Add to dashboard Cite

Psoriasis is a common chronic immune-mediated inflammatory skin disorder and begins in childhood in almost one-third of the cases. Although children present with the same clinical subtypes of psoriasis seen in adults, lesions may differ in distribution and morphology, and their clinical symptoms at presentation may vary from those reported by adult patients. Nevertheless, diagnosis of psoriasis is primarily based on clinical features. Pediatric psoriasis can have a profound long-term impact on the psychological health of affected children. Additionally, pediatric psoriasis has been associated with certain comorbidities, such as obesity, hypertension, hyperlipidemia, diabetes mellitus and rheumatoid arthritis, making early diagnosis and management essential. As guidelines are lacking and most (systemic) treatments are not approved for use in children, treatment of pediatric psoriasis remains a challenge. A prospective, multicenter, international registry is needed to evaluate these treatments in a standardized manner and ultimately to develop international guidelines on pediatric psoriasis. This article reviews current concepts in pediatric psoriasis including epidemiology, clinical features, diagnosis, the role of topical and systemic agents and the association with other morbidities in childhood.

show abstract

Section: Topical Treatmentsmentioning

confidence: 99%

Section: Topical Treatmentsmentioning

confidence: 99%

Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities

et al. 2015

View full text Add to dashboard Cite

show abstract

“…While being one of the few, if not the only, tools made for pediatric psoriasis, it has not been widely adapted especially since it only looks at a specific subset of psoriasis. For example, Oostveen et al [42] used it in their prospective observational study. While they did not include an adolescent subanalysis, overall patients with scalp psoriasis (mean age 10.8 ± 3.7 years) showed a significant improvement in all 3 constructs when scalp psoriasis was treated with calcipotriene/betamethasone dipropionate [42] .…”

Section: Psoriasis-specific Hrql Measurement Tool: Children's Scalpdementioning

confidence: 99%

“…For example, Oostveen et al [42] used it in their prospective observational study. While they did not include an adolescent subanalysis, overall patients with scalp psoriasis (mean age 10.8 ± 3.7 years) showed a significant improvement in all 3 constructs when scalp psoriasis was treated with calcipotriene/betamethasone dipropionate [42] . Further studies are needed for a deeper comprehension of its strengths and limitations overall and in an adolescent population, but it may have potential use and could be used as a model for further psoriasis-specific HRQL measurement tools.…”

Section: Psoriasis-specific Hrql Measurement Tool: Children's Scalpdementioning

confidence: 99%

Systematic Review of Health-Related Quality of Life in Adolescents with Psoriasis

et al. 2016

View full text Add to dashboard Cite

Background: Many cases of psoriasis begin in adolescence. The affected adolescents face the combined physical and psychosocial challenges of their disease-free peers with the added complexity of a visible disease. Objective: To review the impact of psoriasis on the health-related quality of life (HRQL) in adolescents as compared to their peers with other chronic diseases and to determine the best tools to measure HRQL in this population. Methods: A systematic literature review was completed using PubMed. Results: 256 publications were screened for inclusion, 37 were relevant to objectives and included in the systematic review. Most studies are pediatric psoriasis studies with an adolescent subgroup, very few are dedicated to solely addressing HRQL in adolescents with psoriasis. Adolescents with psoriasis face both the challenges similar to an adult psoriasis population in addition to the complexities inherent to healthy adolescents. Studies often use a general pediatric HRQL measure, PedsQL 4.0, or a dermatology-specific measure adapted from an adult questionnaire. Only one psoriasis-specific measurement tool exists, and it is specifically for scalp psoriasis. Conclusion: Both dermatologists and primary care physicians should treat the visible cutaneous lesions and disease comorbidities and address the psychosocial impact of psoriasis in their adolescent patients. Use of both a general and dermatology-specific HRQL questionnaire may allow physicians to better identify the impact of the disease and recognize improvement or impairment over time.

show abstract

“…Three studies used the compounded formulation of calcipotriol and betamethasone dipropionate. 26 – 28 In a prospective cohort study, 73 children (aged 3–18 years) with plaque-type psoriasis were treated with calcipotriol/betamethasone dipropionate ointment once daily for 4 weeks and 4 days a week thereafter, with a median treatment duration of 35 weeks. An improvement of the PASI score was noticeable after 1 week and progressed at weeks 12 and 24, with maintenance of improvement thereafter to week 35.…”

Section: Managementmentioning

confidence: 99%

Psoriasis in children

Pinson¹,

Sotoodian

Fiorillo³

2016

PTT

View full text Add to dashboard Cite

The clinical presentation, disease associations, and diverse treatment modalities in overcoming the challenges of managing pediatric psoriasis have been extensively summarized in this article. An extensive literature review revealed the differences in presentation of psoriasis during infancy, childhood, and adolescence. We also summarized the latest topical, systemic, and biological modalities in treating recalcitrant psoriasis. The association of psoriasis with juvenile arthritis and obesity and the significant influence of the disease on the children’s quality of life were explored. The clinical presentation of psoriasis can evolve during the child’s lifespan. While many treatment modalities already exist for treating pediatric psoriasis, some of the new biologics that are approved for adult patients have not been investigated in the pediatric population and no algorithm exists for their use in this population. Large clinical studies in the future will enhance our understanding with regards to their safety and potential implications in pediatric populations.

show abstract

Treatment of paediatric scalp psoriasis with calcipotriene/betamethasone dipropionate scalp formulation: effectiveness, safety and influence on children's quality of life in daily practice

Abstract: In a daily clinical practice cohort of children with scalp psoriasis, calcipotriene/betamethasone dipropionate scalp formulation was effective with a 32.1% improvement of PSSI at week 12 and a maintenance of this effect until 48 weeks of follow-up, in combination with improvement of QoL.

Cited by 26 publications

References 23 publications

Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities

Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities

Systematic Review of Health-Related Quality of Life in Adolescents with Psoriasis

Psoriasis in children

Contact Info

Product

Resources

About